Policy | December 04, 2025
Promotion of indigenous pharmaceutical manufacturing
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Patients can now get the starting 2.5 mg dose for $299 per month
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The audit was completed with zero critical and zero major observations
Subscribe To Our Newsletter & Stay Updated
